ArticleEinstein (Sao Paulo, Brazil)2025
A cross-sectional study on the expression of fibrinolytic system components and metalloproteinase-9 in women with early-stage and metastases breast cancer in Tucumán, Argentina.
Article in Einstein (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of matrix metalloproteinase 9 in immune-mediated skin diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, standard coagulation, t-PA, PAI-1, DD, and MMP-9 tests were performed in a specific population of patient with early and metastatic breast cancer in Tucumán, Argentina. Only PAI-1 and MMP-9 levels increased in patients with early-stage breast cancer, suggesting that they may have evolved aggressively.
background■ No clinically significant differences were observed in platelet counts or global coagulation test results.
background■ t-PA values decreased in patients with metastases.
background■ PAI-1, DD, and MMP-9 levels increased in patients with metastases.
background■ High levels of PAI-1 and MMP-9 in the early stages could indicate an aggressive course in patients.
objectiveThe hemostatic and matrix metalloproteinase (MMP) systems are known to be altered in patients with breast cancer. This cross-sectional study aimed to explore the fibrinolysis components values and MMP-9 levels in a specific population of patients with early breast cancer and metastatic breast cancer in Tucumán, Argentina.
methodsThis cross-sectional study included 63 patients without pathology or with benign breast pathology (GA Group), 48 patients with newly diagnosed primary breast cancer (GB Group), and 65 patients with metastatic breast cancer (GC Group). Levels of standard coagulation tests, tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), D-dimer (DD), and matrix metalloproteinases-9 (MMP-9) were measured in all groups.
resultsPAI-1 and MMP-9 levels were higher in patient with early breast cancer than those with benign disease. However, the GC Group showed significantly higher PAI-1, DD, and MMP-9 levels than the GA Group. Furthermore, the t-PA concentrations in the GC Group were lower than those in the Control Group.
conclusionOur findings suggest that higher levels of PAI-1 and MMP-9 in patients with early-stage breast cancer may be associated with a subgroup of patients with more aggressive disease progression. In addition, significant alterations in t-PA, PAI-1, DD, and MMP-9 concentrations were observed in advanced stages of the disease. However, basic laboratory tests, such as global coagulation tests, do not effectively differentiate stages in breast cancer. Therefore, further study is needed to explore these findings in greater detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.